4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.
Aged
Antibodies, Antineutrophil Cytoplasmic
/ immunology
Antibodies, Monoclonal
/ immunology
Antibody Affinity
Antibody Specificity
B-Lymphocytes
/ enzymology
Binding Sites, Antibody
Biomarkers
/ metabolism
Case-Control Studies
Cell Line
Epitope Mapping
Epitopes
Female
Glycosylation
Granulomatosis with Polyangiitis
/ diagnosis
Humans
Male
Middle Aged
Myeloblastin
/ immunology
Neutrophil Activation
Proof of Concept Study
anti-neutrophil cytoplasmic antibodies
epitope
granulomatosis with polyangiitis
human neutrophils
proteinase 3
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
06
2020
accepted:
01
09
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Granulomatosis with polyangiitis (GPA) is a severe autoimmune vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) mainly targeting proteinase 3 (PR3), a neutrophilic serine proteinase. PR3-ANCA binding to membrane-bound PR3 on neutrophils induce their auto-immune activation responsible for vascular lesions. However, the correlation between PR3-ANCA level and disease activity remains inconsistent, suggesting the existence of non-pathogenic PR3-ANCA. In order to prove their existence, we immortalized B lymphocytes from blood samples of GPA patients in remission having persistent PR3-ANCA to isolate non-activating PR3-ANCA. We obtained for the first time a non-activating human IgG1κ anti-PR3 monoclonal antibody (mAb) named 4C3. This new mAb binds soluble PR3 with a high affinity and membrane-bound PR3 on an epitope close to the PR3 hydrophobic patch and in the vicinity of the active site. 4C3 is able to bind FcγRIIA and FcγRIIIB and has a G2F glycosylation profile on asparagine 297. 4C3 did not induce activation of neutrophils and could inhibit human polyclonal PR3-ANCA-induced activation suggesting that 4C3 is non-pathogenic. This characteristic relies on the recognized epitope on PR3 rather than to the Fc portion properties. The existence of non-pathogenic PR3-ANCA, which do not activate neutrophils, could explain the persistence of high PR3-ANCA levels in some GPA patients in remission and why PR3-ANCA would not predict relapse. Finally, these results offer promising perspectives particularly regarding the understanding of PR3-ANCA pathogenicity and the development of new diagnostic and therapeutic strategies in GPA.
Identifiants
pubmed: 33101296
doi: 10.3389/fimmu.2020.573040
pmc: PMC7546423
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Antibodies, Monoclonal
0
Biomarkers
0
Epitopes
0
Myeloblastin
EC 3.4.21.76
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
573040Informations de copyright
Copyright © 2020 Granel, Lemoine, Morello, Gallais, Mariot, Drapeau, Musnier, Poupon, Pugnière, Seren, Nouar, Gouilleux-Gruart, Watier, Korkmaz and Hoarau.
Références
Front Immunol. 2018 Apr 09;9:680
pubmed: 29686675
Clin Exp Immunol. 1999 Oct;118(1):171-9
pubmed: 10540175
Clin Exp Immunol. 1991 Mar;83(3):379-86
pubmed: 1848489
J Mol Biol. 1996 Aug 16;261(2):267-78
pubmed: 8757293
Exp Nephrol. 1995 Jul-Aug;3(4):249-56
pubmed: 8590038
Clin Exp Immunol. 2014 Jun;176(3):363-72
pubmed: 24666336
RMD Open. 2017 Jun 15;3(1):e000449
pubmed: 28955487
J Am Soc Nephrol. 2015 Mar;26(3):537-42
pubmed: 25324502
Curr Rheumatol Rep. 2019 Dec 26;21(12):76
pubmed: 31879818
Semin Immunopathol. 2013 Jul;35(4):411-21
pubmed: 23385856
Clin Exp Immunol. 2002 Sep;129(3):562-70
pubmed: 12197900
Arthritis Rheum. 2011 Jul;63(7):2105-15
pubmed: 21437874
J Immunol. 2018 Nov 15;201(10):3096-3105
pubmed: 30322966
J Autoimmun. 2010 Dec;35(4):299-308
pubmed: 20810247
Arthritis Rheum. 2001 Apr;44(4):921-30
pubmed: 11315931
Kidney Int. 1995 Jun;47(6):1528-36
pubmed: 7643521
J Am Soc Nephrol. 2010 Jul;21(7):1103-14
pubmed: 20448018
J Leukoc Biol. 2006 Dec;80(6):1424-33
pubmed: 16997860
Clin Exp Immunol. 2003 Mar;131(3):528-35
pubmed: 12605707
J Proteome Res. 2015 Apr 3;14(4):1657-65
pubmed: 25761865
Ann Rheum Dis. 2019 May;78(5):709-711
pubmed: 30514699
Front Immunol. 2016 Jun 30;7:256
pubmed: 27446086
Pharmacol Rev. 2016 Jul;68(3):603-30
pubmed: 27329045
Autoimmun Rev. 2014 Jul;13(7):742-50
pubmed: 24657512
Ann Rheum Dis. 2016 Apr;76(4):647-653
pubmed: 27481830
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Am J Respir Cell Mol Biol. 2001 Jun;24(6):747-54
pubmed: 11415941
Autoimmun Rev. 2009 May;8(6):510-4
pubmed: 19185066
J Clin Immunol. 2003 Nov;23(6):460-8
pubmed: 15031633
Curr Chem Genomics. 2009 May 28;3:22-32
pubmed: 20161833
Biochem J. 2002 Sep 15;366(Pt 3):965-70
pubmed: 12088507
Clin Exp Immunol. 2012 Sep;169(3):220-8
pubmed: 22861361
J Immunol. 2010 Jul 1;185(1):387-99
pubmed: 20530264
Pharmacol Rep. 2016 Dec;68(6):1276-1284
pubmed: 27689755
Ann Rheum Dis. 2015 Jan;74(1):177-84
pubmed: 24243925
Front Immunol. 2019 Aug 27;10:1958
pubmed: 31507592
Immunology. 2009 Oct;128(2):236-44
pubmed: 19740380
Kidney Int. 2018 Jul;94(1):139-149
pubmed: 29606398
Clin Chem. 1995 Sep;41(9):1391-7
pubmed: 7656455
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
Kidney Int. 2010 Sep;78(6):590-7
pubmed: 20592714
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4115-9
pubmed: 2161532
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Ann Rheum Dis. 2018 Aug;77(8):1150-1156
pubmed: 29724729
Arthritis Rheum. 2000 Sep;43(9):2025-33
pubmed: 11014352
Autoimmun Rev. 2016 Oct;15(10):978-82
pubmed: 27481040
Clin Exp Immunol. 2002 Jul;129(1):183-90
pubmed: 12100039
Nat Clin Pract Rheumatol. 2006 Apr;2(4):174-5
pubmed: 16932679
JCI Insight. 2017 Jan 26;2(2):e87379
pubmed: 28138552
Ann Rheum Dis. 2011 Mar;70(3):488-94
pubmed: 21109517
MAbs. 2009 Jul-Aug;1(4):332-8
pubmed: 20073133
PLoS One. 2019 Feb 28;14(2):e0213215
pubmed: 30818380
J Clin Invest. 2013 Apr;123(4):1773-83
pubmed: 23549081
Kidney Int. 2001 Jan;59(1):147-59
pubmed: 11135067
Clin Exp Immunol. 1995 Aug;101(2):227-32
pubmed: 7648707
Clin Exp Immunol. 2001 Jan;123(1):170-7
pubmed: 11168015
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
J Leukoc Biol. 2000 Mar;67(3):396-404
pubmed: 10733101
Clin Exp Immunol. 2004 Sep;137(3):451-9
pubmed: 15320893
J Leukoc Biol. 2005 Jan;77(1):33-43
pubmed: 15459232
Autoimmun Rev. 2014 Mar;13(3):313-8
pubmed: 24225075
Nat Rev Rheumatol. 2014 Aug;10(8):463-73
pubmed: 25003769
Ann Rheum Dis. 2007 May;66(5):676-82
pubmed: 17204568
J Biol Chem. 2007 Jan 19;282(3):1989-97
pubmed: 17088257
Arthritis Rheumatol. 2016 Jul;68(7):1700-10
pubmed: 26882078
J Rheumatol. 2005 Nov;32(11):2167-72
pubmed: 16265696
Inflammation. 2000 Dec;24(6):559-69
pubmed: 11128053
Arthritis Res Ther. 2018 Sep 20;20(1):213
pubmed: 30236159
J Leukoc Biol. 2003 Jul;74(1):3-15
pubmed: 12832437
J Immunol. 2016 Jan 15;196(2):607-13
pubmed: 26685205